An interview with Richard Brudnick, Senior VP, Corporate Development, Biogen

De-risking has evolved from literature searches to the cultivation of many wide-ranging relationships throughout the life sciences strata, according to Richard Brudnick, Senior VP, Corporate Development at Biogen. In a recent interview, Brudnick outlined key strategies to accessing innovation and “de-risking” risk through collaboration. more »

MorphoSys has acquired all outstanding shares of the Dutch biopharmaceutical company Lanthio Pharma B.V. more »

Alexion Pharmaceuticals have entered into a definitive agreement pursuant to which Alexion will acquire Synageva for consideration of $115 in cash and 0.6581 Alexion shares, for each share of Synageva, implying a total per share value of $230 based on the nine day volume-weighted average closing price of Alexion stock through May 5, 2015. more »

Celgene and Quanticel Pharmaceuticals announced a definitive share purchase agreement under which Celgene will acquire Quanticel more »

Immunocore will conduct a Phase Ib/II clinical trial combining checkpoint inhibitors MEDI4736 (anti-PD-L1) and/or tremelimumab (anti-CTLA-4) with IMCgp100 more »

Mesoblast has entered into an Agreement with Celgene more »

MorphoSys has regained rights to MOR202 from Celgene more »

Open Monoclonal Technology announced license that provides Celgene with unlimited access to OMT’s proprietary OmniRat, OmniMouse and OmniFlic platforms for generation of human antibody therapeutics more »

MedImmune and Joslin Diabetes Center announced a three-year research collaboration to develop new medicines for the treatment of diabetes, obesity, and related metabolic disorders more »

Blueprint Medicines announced a strategic collaboration with Alexion to discover, develop and commercialize novel drug candidates more »